Syncona Partners LLP
VC Fund
London, United Kingdom
Syncona Partners LLP is a VC fund in London focused on Biotechnology and Medical. Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Their vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.They seek to partner with the best, brightest and most ambitious minds in scienceto build globally competitive businesses. They take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. They focus on delivering dramatic efficacy for patients in areas of high unmet need.Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in their business. They make a donation of 0.3% of Net Asset Value to a range of charities each year.
- Total investments:
- 75
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries Syncona Partners LLP invests in
Stages Syncona Partners LLP invests in
Countries Syncona Partners LLP invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $1.9M–$17M
- Series A
- $13M–$87M
- Series B
- $29M–$156M
Investment Focus
Industry
- Biotechnology 19 (25%)
- Medical 9 (12%)
- Health Care 9 (12%)
- Therapeutics 8 (11%)
- Life Science 6 (8%)
Stage
- Series A 17 (23%)
- Series B 16 (21%)
- Seed 7 (9%)
- Series C 6 (8%)
- Funding Round 1 (1%)
Country
- United Kingdom 18 (24%)
- United States 4 (5%)
- Switzerland 2 (3%)
- The Netherlands 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Edward Hodgkin
Partner
|
Partner | Total investments: 9 | Find email | |
Magdalena Jonikas
Partner
|
Partner | Total investments: 4 | Find email | |
Chris Hollowood
Chief Investment Officer
|
Chief Investment Officer | Total investments: 11 | Find email | |
Chris Hollowood
Chief Investment Officer
|
Chief Investment Officer | Total investments: 8 | Find email | |
Christian Groendahl
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Re-Aim Therapeutics
|
Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions. | $9.4M / Seed / May 18, 2026 | |
Apini Therapeutics
|
Apini is a creating novel small chemical two most prevalent types of inflammatory bowel disease. | $2.4M / Seed / Jun 11, 2025 | |
| Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally. | $104.5M / Series B / Oct 09, 2024 | ||
Resolution Therapeutics
|
Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases. | $28.9M / Series B / Oct 03, 2024 | |
| Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted, With the potential to dramatically improve patient outcomes. | $20.9M / Series A / Jun 20, 2024 | ||
| iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M / Series B / Jun 20, 2024 | ||
| Spur Therapeutics is a clinical-stage biotechnology business dedicated to creating life-changing medicines for crippling chronic illnesses. | $50M / Private Equity / Jun 17, 2024 | ||
| Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $170M / Series B / Jun 03, 2024 | ||
| SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders. | $10M / Venture - Series Unknown / Oct 04, 2023 | ||
| Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $120.1M / Series A / Jun 12, 2023 | ||
| See all 75 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Syncona Partners LLP invest in?
Syncona Partners LLP invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 75 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Syncona Partners LLP's check size?
Syncona Partners LLP typically joins rounds of $1.9M–$17M at Seed, $13M–$87M at Series A and $29M–$156M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Syncona Partners LLP participates in.
How do I contact Syncona Partners LLP?
Public channels for Syncona Partners LLP include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Syncona Partners LLP?
The team at Syncona Partners LLP includes Edward Hodgkin (Partner), Magdalena Jonikas (Partner) and Chris Hollowood (Chief Investment Officer), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
